This practice, the HHS inspector general said, could harm patients, the government and taxpayers because people might take pricey drugs instead of cheaper ones.
PCMA said the changes wouldn’t be as disruptive as others argued, and highlighted several classes of drugs
Pharmaceutical companies gave at least $116 million to patient advocacy groups in a single year
Mark Merritt said “we always support, as an industry, patients paying lower price at the counter…it’s an outlier practice.”
A recent article (“The Corporate Scam that Even Trump Opposes: PBMs”) attacks the one industry that is both reducing prescription drug costs and improving quality: pharmacy benefit managers (PBMs). The White House fiscal year 2019 budget included many cost-saving items PBMs have
Greater competition is the answer, Mr. Merritt said, and he praised recent efforts by the Food and Drug Administration
According to University of Chicago economics professor Casey Mulligan, pharmacy benefit companies provide many services to participants across the healthcare system. The value to society of all of these services is a whopping $145 billion. Every. Single. Year. What would happen to
Pharmacy benefit companies play an important and unique role in the drug supply and payment chain. Employers, labor unions, health plans, government agencies, drug companies, pharmacies, and most importantly patients all benefit from pharmacy benefit company services.
©2024 PCMA. All Rights Reserved.
